Post by
palinc2000 on Nov 18, 2020 9:23am
Gilead
https://investors.gilead.com/news-releases/news-release-details/gilead-announces-investigational-long-acting-hiv-1-capsid
Comment by
Wino115 on Nov 18, 2020 9:44am
So 2 to 3 years away, no safety data yet and will be third product for what appears to be a rather small market. Can't see them wanting to spend a whole lot of time or money on that, but go for it. Thankfully THTX will be well on its way in other more profitable areas by then.
Comment by
palinc2000 on Nov 18, 2020 10:03am
''A third product for a relatively small market"" Why would GILD spend time amd money on drug for which the market is small? Maybe the market is much larger than what Trogarzos sales have shown so far ,,,,,,I think Levesque is still convinced that this is the case
Comment by
ggg088 on Nov 18, 2020 11:27am
Both R & D and marketing need financing support, they must raise enough funding to increase revenue and meet R&D investment. So key point is still to get more institutional investors invloved in.
Comment by
qwerty22 on Nov 18, 2020 1:04pm
There is so little appetite for THTX pre-fda decision is it even possible to get the necessary interest?
Comment by
ggg088 on Nov 18, 2020 1:04pm
Spce01, can we suppose once the Thtx price reach up to $5, it would fly over $10 because institutional investors will start to purchase the shares?
Comment by
SPCEO1 on Nov 18, 2020 1:37pm
No. getting over $5 would help but it is no guarantee that the stock would just jump higher from that point. It would be tied to the progress the company was making. The fundamentals always win in the end and without good progress on NASH or cancer, the stock will not be soaring anywhere since Egrifta for Lipo and Trogarzo is not likely to drive the share price higher at this point.
Comment by
Wino115 on Nov 18, 2020 2:15pm
I suppose they could go the convertible route again too if they get the price up a bit. Do a $100-200mil deal, call the old one. Maybe you could get a strike of $7-10-ish and a 5% rate. Not bad for $200mil of borrowing. It would at least limit the dilution some from issueing at $4-6 level.
Comment by
SPCEO1 on Nov 18, 2020 2:52pm
I could easily see something like that happening. I am not sure I like it but it is better than a straight equity offering.
Comment by
realitycheck4u on Nov 19, 2020 10:09am
This post has been removed in accordance with Community Policy
Comment by
ggg088 on Nov 19, 2020 10:11am
Can we suppose that Thtx will push up the SP if they want to dilute shares?
Comment by
scarlet1967 on Nov 18, 2020 12:14pm
If you look at the alternative site infusion, link below there are several conditions to get approved for the program and probably added costs. Company needs to remove all these hurdles so patients can have easy access to Trogarzo. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/index/commercial/provider-administered-drugs-soc-01012021.pdf